Actively Recruiting
Study of Dolutegravir Drug Levels During Weekly Rifapentine and Isoniazid Treatment to Prevent Tuberculosis in Children with HIV Aged 4 Weeks to Under 12 Years
Led by Brigham and Women's Hospital · Updated on 2026-07-30
25
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Tuberculosis TB is a leading cause of death among children living with HIV, but there is limited data on how new TB prevention treatments work in this group. This research evaluates the pharmacokinetics, or how drugs move through the body, of weekly rifapentine and isoniazid 3HP combined with dolutegravir in children with HIV. The study focuses on filling knowledge gaps about these short-course TB prevention regimens in vulnerable pediatric patients. Children aged 2 to 11 years receive standard HIV treatment with dolutegravir plus weekly rifapentineisoniazid for 12 weeks, following World Health Organization guidelines for latent TB infection treatment. Children under 2 years get standard dolutegravir-based HIV treatment, a single dose of weekly rifapentineisoniazid for study purposes, then daily isoniazid prophylaxis. The studys main intervention involves additional blood sampling to measure drug levels and biomarkers, with clinical and laboratory safety monitoring during the 48-week study. Participants undergo pharmacokinetic blood sampling at weeks 4, 6, and 7 to assess drug concentrations, along with biomarker testing to understand drug activity. Safety labs and clinical monitoring continue throughout the study period. Researchers will measure dolutegravir exposure during rifapentineisoniazid treatment as the primary outcome, alongside rifapentine levels and adverse events up to week 48. The study lasts approximately 48 weeks per participant.
CONDITIONS
Brief Title
Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention
Research Team
H
Holly Rawizza, MD, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here